Immuno-Oncology Portfolio

Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio

Osaka, Japan & Brisbane, Calif., United States: Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active…

Read More »